You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis
|
|---|---|
| Published in |
EBioMedicine, May 2015
|
| DOI | 10.1016/j.ebiom.2015.05.011 |
| Pubmed ID | |
| Authors |
Mitchell S. Stark, Kerenaftali Klein, Benjamin Weide, Lauren E. Haydu, Annette Pflugfelder, Yue Hang Tang, Jane M. Palmer, David C. Whiteman, Richard A. Scolyer, Graham J. Mann, John F. Thompson, Georgina V. Long, Andrew P. Barbour, H. Peter Soyer, Claus Garbe, Adrian Herington, Pamela M. Pollock, Nicholas K. Hayward |
| Abstract |
The overall 5-year survival for melanoma is 91%. However, if distant metastasis occurs (stage IV), cure rates are < 15%. Hence, melanoma detection in earlier stages (stages I-III) maximises the chances of patient survival. We measured the expression of a panel of 17 microRNAs (miRNAs) (MELmiR-17) in melanoma tissues (stage III; n = 76 and IV; n = 10) and serum samples (collected from controls with no melanoma, n = 130; and patients with melanoma (stages I/II, n = 86; III, n = 50; and IV, n = 119)) obtained from biobanks in Australia and Germany. In melanoma tissues, members of the 'MELmiR-17' panel were found to be predictors of stage, recurrence, and survival. Additionally, in a minimally-invasive blood test, a seven-miRNA panel (MELmiR-7) detected the presence of melanoma (relative to controls) with high sensitivity (93%) and specificity (≥ 82%) when ≥ 4 miRNAs were expressed. Moreover, the 'MELmiR-7' panel characterised overall survival of melanoma patients better than both serum LDH and S100B (delta log likelihood = 11, p < 0.001). This panel was found to be superior to currently used serological markers for melanoma progression, recurrence, and survival; and would be ideally suited to monitor tumour progression in patients diagnosed with early metastatic disease (stages IIIa-c/IV M1a-b) to detect relapse following surgical or adjuvant treatment. |
X Demographics
The data shown below were collected from the profiles of 17 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 5 | 29% |
| United Kingdom | 2 | 12% |
| United States | 1 | 6% |
| Costa Rica | 1 | 6% |
| Unknown | 8 | 47% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 59% |
| Scientists | 3 | 18% |
| Practitioners (doctors, other healthcare professionals) | 2 | 12% |
| Science communicators (journalists, bloggers, editors) | 2 | 12% |
Mendeley readers
The data shown below were compiled from readership statistics for 93 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Denmark | 1 | 1% |
| Unknown | 92 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 18% |
| Student > Ph. D. Student | 16 | 17% |
| Student > Master | 11 | 12% |
| Student > Bachelor | 11 | 12% |
| Other | 7 | 8% |
| Other | 17 | 18% |
| Unknown | 14 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 24 | 26% |
| Medicine and Dentistry | 20 | 22% |
| Agricultural and Biological Sciences | 19 | 20% |
| Immunology and Microbiology | 4 | 4% |
| Computer Science | 2 | 2% |
| Other | 9 | 10% |
| Unknown | 15 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 57. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 November 2018.
All research outputs
#740,266
of 25,374,917 outputs
Outputs from EBioMedicine
#379
of 4,009 outputs
Outputs of similar age
#8,670
of 279,139 outputs
Outputs of similar age from EBioMedicine
#3
of 65 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,009 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 32.0. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,139 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.